AG
ACHN

Artal Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Artal Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-750,000
Closed -$2.78M – 124
2018
Q1 		$2.78M Hold
750,000
– – 0.03% 89
2017
Q4 		$2.16M Sell
750,000
-250,000
-25% -$908K 0.03% 94
2017
Q3 		$4.49M Buy
+1,000,000
New +$4.44M 0.08% 67

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Artal Group's ACHN Position: Q2 2018 in Review

Artal Group sold out of Achillion Pharmaceuticals (ACHN) in Q2 2018, closing a stake of 750,000 shares — an estimated $2.78M sold.

Artal Group first reported a position in ACHN in Q3 2017 and held it in 3 quarters. The position peaked at $4.49M in Q3 2017. 124 funds tracked by Wall St. Rank hold ACHN as of Q2 2018.

  • Artal Group reported no remaining Achillion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Artal Group sold 750,000 Achillion Pharmaceuticals shares in Q2 2018, an estimated $2.78M.
  • Artal Group first reported a position in Achillion Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Artal Group's Achillion Pharmaceuticals position peaked at $4.49M in Q3 2017.
  • 124 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2018.

Based on Artal Group's 13F filing for Q2 2018, filed 10 Aug 2018.